Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$104.51 USD

104.51
3,425,759

+0.46 (0.44%)

Updated Dec 8, 2023 04:00 PM ET

After-Market: $104.52 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.96%
2Buy17.61%
3Hold8.96%
4Sell4.80%
5Strong Sell2.32%
S&P50010.64%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (140 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott (ABT) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

In the closing of the recent trading day, Abbott (ABT) stood at $104.94, denoting a +0.57% change from the preceding trading day.

PETQ vs. ABT: Which Stock Is the Better Value Option?

by Zacks Equity Research

PETQ vs. ABT: Which Stock Is the Better Value Option?

Abbott (ABT) Rises Higher Than Market: Key Facts

by Zacks Equity Research

Abbott (ABT) closed the most recent trading day at $104.29, moving +0.64% from the previous trading session.

Wall Street Bulls Look Optimistic About Abbott (ABT): Should You Buy?

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

by Zacks Equity Research

Sector ETF report for IHI

Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT) driven by expansion in the global market and raised guidance.

Abbott (ABT) Benefits From Innovation Amid FX Headwinds

by Zacks Equity Research

Abbott's (ABT) mAbxience collaboration is likely to help introduce cutting-edge medicines in the areas of oncology, women's health and respiratory diseases.

Sheraz Mian headshot

Top Analyst Reports for Novo Nordisk, Bank of America & Netflix

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Bank of America Corporation (BAC) and Netflix, Inc. (NFLX).

PETQ vs. ABT: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PETQ vs. ABT: Which Stock Is the Better Value Option?

Abbott (ABT) Up 5.1% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

What's in the Cards for Medtronic (MDT) in Q2 Earnings?

by Zacks Equity Research

Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal second-quarter performance.

QIAGEN (QGEN) Expands Sample Technologies Line With New Launch

by Zacks Equity Research

QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.

Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase

by Zacks Equity Research

Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.

Abbott (ABT) Just Overtook the 50-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

If You Invested $1000 in Abbott a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.

Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure

by Zacks Equity Research

Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

Charles River (CRL) to Advance AI Drug Discovery With New Pact

by Zacks Equity Research

Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors are optimistic about CVS Health's (CVS) strength in Health Care Benefits business arm and stable solvency position.

Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service

by Zacks Equity Research

Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.

Hologic's (HOLX) Q4 Earnings Beat Estimates, Gross Margin Down

by Zacks Equity Research

Solid year-over-year growth in the Breast Health segment drives Hologic's (HOLX) Q4 performance.

BD (BDX) Q4 Earnings In-Line With Estimates, Margins Contract

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in all its segments and both geographic regions in the fiscal fourth quarter.

Here's Why You Should Retain Boston Scientific (BSX) Now

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX), led by growing demand for WATCHMAN FLX devices and upbeat guidance.